Anti-TNF Therapy for Refractory Colitis in Hospitalized Children

Colitis, Ulcerative Clinical Trial

— ARCH  

Official title:

Multicenter Non-Therapeutic Study of Infliximab for Severe Refractory Colitis in Hospitalized Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02799615
• Other study ID #: 2014-0063; 2015-8753
• Status: Completed
• Start date: May 2016
• Est. completion date: November 2019

Study information

• Verified date: July 2019
• Source: Children's Hospital Medical Center, Cincinnati
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This multicenter study is being conducted to determine whether infliximab exposure after an initial infusion is predictive of early clinical response in hospitalized pediatric patients with severe steroid-refractory UC or IBD-U. This pilot and feasibility study will establish the infrastructure, demonstrate feasibility, and collect preliminary data to support the full study.

Description:

This is a multicenter prospective non-interventional cohort study to identify clinical and biological markers that predict non-response in hospitalized pediatric patients with severe corticosteroid-refractory UC or inflammatory bowel disease unspecified (IBD-U) being initiated on infliximab.

Patients hospitalized with severe UC or IBD-U (PUCAI ≥ 65 on admission) and failing intravenous corticosteroids will be eligible. Blood, stool, and rectal biopsies (if sigmoidoscopy performed for clinical indications) will be collected for translational studies (Aim 3). Patients will receive infliximab per the dose and regimen determined by clinical physician. No standard dosing regimen will be used and the dose of IFX will be determined by the treating physician. Serial PUCAI scores and infliximab levels will be obtained.

Those who are eligible to participate will have serial blood samples taken in association with drug infusions to perform pharmacokinetic/pharmacodynamic modeling of infliximab exposure. Clinical response will be determined using the Pediatric UC Activity Index (PUCAI) questionnaire.

Initially, 6 centers will participate with a minimum target enrollment goal of 36 evaluable pediatric research participants (to a maximum of 40) age > 4 years or < 18 years old with UC or IBD-U (average 6/center).

The primary endpoint will be the relationship between IFX exposure (area under the curve of the PK model) and Day 7 clinical response defined as Pediatric Ulcerative Colitis Activity Index (PUCAI) ≤ 35. Secondary endpoints will be Week 8 clinical remission, and Week 26 steroid-free, colectomy-free remission. We will initially enlist 6 centers, and enroll 36-40 evaluable patients in 2 years.

This study described by this protocol is designed as pilot and feasibility study, which we anticipate will ultimately be expanded to larger study. Therefore, to demonstrate feasibility and begin the development of a biorepository on this patient population, certain biospecimens will be collected for this study and anticipated future translational studies as follows:

• Blood will be used for IFX pharmacokinetic assays (e.g. levels, antibodies) and future biomarker discovery.

• Blood DNA we anticipate will be used for genotype/phenotype correlations and genetic predictors of rapid infliximab clearance and non-response.

• Colon tissue RNA will be used for determining how local gene expression patterns predict or explain infliximab clearance or non-response.

• Colon tissue DNA we anticipate will be used for studies of how the microbiome or epigenetic changes relate to severe UC or response to infliximab.

• Colon tissue will be used for determining the relationship between tissue TNF levels (or other proteins) and infliximab clearance or non-response.

• Stool will be collected for serial measurement of fecal calprotectin and future microbiome studies

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: November 2019
• Est. primary completion date: February 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 17 Years

Eligibility

Inclusion Criteria:

1. Age criteria: = 4 or < 18 years of age

2. Diagnosis of UC or IBD-U by established criteria

3. Admitted to the hospital

4. Colitis extending beyond the rectosigmoid colon

5. PUCAI = 65 at admission and = 45 at first dose of infliximab

6. Treatment with infliximab considered by the treating physician

7. Anticipated follow-up = 6 months from infliximab initiation

8. Permission/assent of parent/guardian and research participant.

Exclusion Criteria:

1. Diagnosis of Crohn's disease

2. Enteric infection with a bacterial pathogen (including clostridium difficile), per review of medical records

3. Colon tissue positive for CMV by PCR, immunohistochemistry, or in situ hybridization, per review of the medical records

4. Colitis currently extending only to the rectosigmoid colon (proctosigmoiditis)

5. Prior treatment with infliximab or other anti-TNF agent

6. Prior treatment with cyclosporine or tacrolimus

7. PUCAI < 45 the day of first infliximab infusion

8. Pregnancy, per review of medical records and verbal report

9. Other poorly controlled medical condition

10. Hepatic disease (AST or Alk Phos > 3 times the upper limit of normal) in the absence of IBD associated liver disease

11. Renal disease (BUN and creatinine >1.5 times the upper limit of normal)

Related Conditions & MeSH terms

• Bowel Diseases, Inflammatory
• Colitis
• Colitis, Ulcerative
• Inflammatory Bowel Diseases

Intervention

Drug:
• Infliximab
No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician

Locations

Country	Name	City	State
Canada	The Hospital for Sick Children	Toronto	Ontario
United States	Emory University School of Medicine	Atlanta	Georgia
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	Connecticut Children's Hospital Medical Center	Hartford	Connecticut
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Rhode Island Hospital	Providence	Rhode Island

Sponsors (2)

Lead Sponsor	Collaborator
Children's Hospital Medical Center, Cincinnati	Crohn's and Colitis Foundation

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint will be the relationship between IFX exposure (area under the curve of the PK model) and Day 7 clinical response defined as Pediatric Ulcerative Colitis Activity Index (PUCAI) <35.	IFX exposure and Day 7 PUCAI	7 days